INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101/110 111010101111101011111 0 0111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/200493 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C07K 16/30 (2006.01) A61P 35/00 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 39/395 (2006.01) G01N 33/53 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/SG2017/050266 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (22) International Filing Date: 22 May 2017 (22.05.2017) Published: — with international search report (Art. 21(3)) (25) Filing Language: English — with sequence listing part of description (Rule 5.2(a)) (26) Publication Language: English (30) Priority Data: 10201604090Y 20 May 2016 (20.05.2016) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). (72) Inventors: DING, Mei Yee Vanessa; c/o Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Singapore 138668 (SG). CHOO, Boon Hwa Andre; c/o Bioprocess- ing Technology Institute, 20 Biopolis Way, #06-01, Sin- gapore 138668 (SG). FONG, Wey Jia; c/o Bioprocessing = Technology Institute, 20 Biopolis Way, #06-01, Singapore = 138668 (SG). Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; = (74) — P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = (81) = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — 1-1 en (54) Title: ANTI-AXL TYROSINE KINASE RECEPTOR ANTIBODIES AND USES THEREOF 0\ i v (57) : The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan © on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment con- con- © jugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a © ---. cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically I N effective amount of the antigen-binding protein, or antigen- binding fragment thereof, therapeutic use of the antigen-binding protein, 1-1 © or ei antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided. O